Legend Biotech Corporation
NASDAQ:LEGNBiotechnology
Healthcare
$16.10 -13.51%
-$4.53 today
- Market cap
- $2.98B
- Beta
- 0.35
- P/E (TTM)
- -21.4
- EPS (TTM)
- -$1.35
52W Low $16.24High $45.30
Volume 2.37M
Average 2.42M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$100.47M
FY 2025 · Annual
Investing Cash Flow
$711.48M
FY 2025 · Annual
Financing Cash Flow
-$300,793.00
FY 2025 · Annual
Cash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (407.2M) | (445.72M) | (520.12M) | (158.13M) | (297.58M) |
| Depreciation & Amortization | 13.92M | 18.39M | 20.45M | 23.36M | 28.9M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 20.16M | 34.34M | 47.68M | 68.94M | 0 |
| Change in Working Capital | 161.83M | 181.03M | (71.34M) | 20.04M | (93.35M) |
| Accounts Receivables | 24.59M | 50.32M | (98.98M) | 93.75M | (132.85M) |
| Inventory | 51K | (13.89M) | (12.71M) | (17.21M) | (4.51M) |
| Accounts Payables | 1.81M | 72.45M | (50.2M) | 14.06M | 44.52M |
| Other Working Capital | 135.39M | 72.16M | 90.54M | (70.57M) | (501.32K) |
| Other Non-Cash Items | 12.82M | 10.68M | 130.06M | (98.24M) | 261.57M |
| Operating Cash Flow | (198.47M) | (201.28M) | (393.28M) | (144.03M) | (100.47M) |
| Capital Expenditures | (45.4M) | (22.28M) | (22.72M) | (14.11M) | (67.58M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (377.96M) | (654.97M) | (4.86B) | (2.71B) | (4.55B) |
| Sales of Investments | 230.08M | 614.86M | 5.08B | 1.93B | 5.33B |
| Other Investing Activities | (4.91M) | (16.05M) | (100.52M) | (54.34M) | 0 |
| Investing Cash Flow | (194.98M) | (77.09M) | 92.79M | (850.54M) | 711.48M |
| Debt Repayment | (1.42M) | (2.6M) | (3.76M) | (4.02M) | 0 |
| Common Stock Issued | 623.44M | 377.64M | 0 | 0 | 3.31M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 4.64M | 2.93M | 795.25M | 9.72M | (3.61M) |
| Financing Cash Flow | 626.66M | 377.98M | 791.49M | 5.7M | (300.79K) |
| Effect of Forex Changes | 34K | (2.51M) | 682K | (2.09M) | 4.37M |
| Net Change in Cash | 233.25M | 97.09M | 491.68M | (990.96M) | 615.09M |
| Free Cash Flow | (243.87M) | (223.56M) | (416M) | (158.14M) | (168.04M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$297.6M
+ D&A$28.9M
+ Stock-Based Comp$0
+ Deferred Tax$0
- Working Capital-$93.3M
+ Other Non-Cash$261.6M
= Operating Cash Flow-$100.5M
- Capex-$67.6M
= Free Cash Flow-$168.0M
Analysis
FY2025 free cash flow is -$168.0M. FCF conversion is 56.5% of net income. Operating cash flow was -$100.5M, with capex of -$67.6M. The largest bridge item is Other Non-Cash at $261.6M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 6-K | 6-K filing | Nov 10, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 5, 2026 | |
| 6-K | 6-K filing | Nov 4, 2026 | |
| 6-K | 6-K filing | Oct 15, 2026 | |
| 6-K | 6-K filing | Oct 13, 2026 |
Does LEGN generate free cash flow?
Legend Biotech Corporation (LEGN) generated -$168.04M of free cash flow in fiscal 2025.
How much operating cash flow does LEGN produce?
Operating cash flow was -$100.47M, before capital expenditures of $67.58M.
Continue the stock analysis
Jump to another research area for this company.